Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCFinancial_Report.xls
10-Q - QUARTERLY REPORT - VENTRUS BIOSCIENCES INCv326006_10q.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR6.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR4.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR7.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR1.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR2.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR9.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR18.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR17.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR22.htm
EX-31.1 - CERTIFICATION - VENTRUS BIOSCIENCES INCv326006_ex31-1.htm
EX-32.1 - CERTIFICATION - VENTRUS BIOSCIENCES INCv326006_ex32-1.htm
EX-31.2 - CERTIFICATION - VENTRUS BIOSCIENCES INCv326006_ex31-2.htm
EX-32.2 - CERTIFICATION - VENTRUS BIOSCIENCES INCv326006_ex32-2.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR5.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR13.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR19.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR11.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR15.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR14.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR12.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR20.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR23.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR16.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR21.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR3.htm
XML - IDEA: XBRL DOCUMENT - VENTRUS BIOSCIENCES INCR10.htm
v2.4.0.6
Organization, Business and Basis of Presentation
9 Months Ended
Sep. 30, 2012
Organization, Business and Basis Of Presentation [Abstract]  
Organization, Business and Basis of Presentation

Note 1 — Organization, Business and Basis of Presentation:

 

Organization and business:

 

Ventrus BioSciences Inc. (“Ventrus” or the “Company”) is a specialty pharmaceutical company currently focused on the development and commercialization of late-stage prescription drugs addressing gastrointestinal problems, specifically anal disorders. Ventrus was incorporated in the State of Delaware on October 7, 2005 and commenced operations in April 2007.

 

Basis of presentation:

 

The accompanying condensed balance sheet as of December 31, 2011, which has been derived from the Company’s audited financial statements, and the unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information presented not misleading. The unaudited interim condensed financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the results for the periods presented. All such adjustments are of a normal and recurring nature. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K and Form 10-K/A for the year ended December 31, 2011 filed on March 14 and June 13, 2012, respectively. The operating results presented in these unaudited condensed financial statements are not necessarily indicative of the results that may be expected for any future periods.

 

Capital Resources:

 

The Company has not derived any revenue from product sales to date as its products have not been approved for sale by the U.S. Food and Drug Administration (“FDA”) or any foreign regulatory agency. Since inception, the Company’s operations have been financed primarily through the sale of equity securities, the proceeds from the exercise of warrants and stock options and issuance of debt. The Company has incurred losses from operations and negative cash flows since inception and expects to continue to incur substantial losses for the foreseeable future as it continues product development. As a result, the Company may need to obtain additional funds to finance its operations in the future. In July 2011, the Company raised net proceeds of approximately $47,600,000 in a secondary offering of its equity securities. In May and June 2012, the Company raised approximately $4,166,000 in an at-the-market common equity sales program. Until the Company can generate significant cash from its operations, it intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, or other arrangements and it cannot assure such funding will be available on reasonable terms, or at all. The Company currently has sufficient funds to meet its operating requirements and scheduled regulatory and development activities through the second quarter of 2014.